News
Avivia participates in a consortium to develop new medicines to treat and prevent COVID-19
The public-private consortium to run this project includes leading academic groups and for-profit parties with a track record in drug discovery and development, extensive knowledge of medicinal chemistry and virology. The development of an effective treatment and prophylactic agent for COVID-19 will have a profound social and economic impact today. In addition, a broad spectrum antiviral will help to contain/curb future epidemic coronavirus outbreaks and to treat future patients.
How to make a DIY Hand Disinfection Spray
With the current corona virus, face caps and disinfectant soap and hand gel are hardly available in the stores. Although you can discuss the usefulness of face masks, washing your hands regularly is an effective way to reduce the odds of getting sick. If water isn’t available a hand disinfection spray for the road is very useful.
Development of a new leishmaniasis drug wins EU funding
TT4CL (Targeted treatment for cutaneous leishmaniasis) is a new Horizon 2020-funded project which aims to reduce the burden of Neglected Infectious Diseases (NID) and its social and economic impacts. Horizon 2020, the European Union’s (EU) research and innovation programme, helps to bridge the gap between preclinical and clinical development and thus helps to advance promising new drug candidates along the development pipeline. The TT4CL consortium, which brings together partners from academia and industry in Europe and disease-endemic countries, has been awarded EUR3.75 million to develop an oral treatment, D121, against one of the most neglected tropical diseases, cutaneous leishmaniasis.
Avivia attends WHO meeting on neglected tropical skin diseases
Marleen De Vriese and Hans Platteeuw are attending this weeks’ biannual meeting on Buruli Ulcer and Skin NTD’s at the WHO headquarters in Geneva (Switzerland).